Preferred Label : Durvalumab/Tremelimumab Regimen;
NCIt synonyms : Imfinzi/Imjudo Regimen; Tremelimumab/Durvalumab; Tremelimumab/Durvalumab Regimen; Durvalumab/Tremelimumab; Durvalumab/Tremelimumab-actl Regimen; Imjudo/Imfinzi;
NCIt related terms : Durvalumab and Tremelimumab;
NCIt definition : A regimen consisting of durvalumab and tremelimumab that may be used in the treatment
of unresectable hepatocellular carcinoma (uHCC).;
NCI Metathesaurus CUI : CL1904893;
Codes from synonyms : 7161;
Origin ID : C191202;
UMLS CUI : C5784294;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
https://www.has-sante.fr/jcms/p_3448228/fr/imjudo-/-imfinzi-tremelimumab-/-durvalumab-carcinome-hepato-cellulaire-chc
2023
false
false
false
France
antineoplastic combined chemotherapy protocols
Durvalumab/Tremelimumab Regimen
insurance, health, reimbursement
treatment outcome
infusions, intravenous
adult
Advanced Adult Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Child-Pugh Class A
ECOG Performance Status 0
ECOG Performance Status 1
evaluation of the transparency committee
carcinoma, hepatocellular
durvalumab
tremelimumab
---
